What is Venus Medtech?
Founded in 2009, Venus Medtech specializes in the design, development, and commercialization of transcatheter heart valve products. The company is widely recognized as the leading player in China by implantation volume, holding a commanding 79.3% market share in the TAVR segment as of 2018. Its flagship product, VenusA-Valve, holds the distinction of being the first NMPA-approved TAVR device in China, granting the firm a significant first-mover advantage. With a comprehensive pipeline covering all four heart valves and a portfolio of nearly 400 patents, Venus Medtech operates at the intersection of high-barrier medical engineering and clinical excellence, effectively differentiating itself from domestic and international competitors.
How much funding has Venus Medtech raised?
Venus Medtech has raised a total of $37M across 1 funding round:
Private Equity
$37M
Private Equity (2016): $37M with participation from Goldman Sachs
Key Investors in Venus Medtech
Goldman Sachs
Goldman Sachs is a leading global investment banking, securities, and investment management firm. It provides a wide range of financial services to corporations, governments, and institutional and individual clients, including mergers and acquisitions advisory, underwriting, asset management, securities trading, and wealth management.
What's next for Venus Medtech?
Looking ahead, Venus Medtech is positioned to capitalize on its established infrastructure to accelerate the adoption of its next-generation cardiovascular therapies. The strategic deployment of its recent financing will likely focus on expanding clinical trials, enhancing manufacturing capabilities, and deepening its intellectual property moat. By maintaining its focus on high-entry-barrier medical devices, the company is well-equipped to navigate the complexities of the global heart valve market, potentially setting the stage for further international expansion and sustained long-term value creation for its stakeholders.
See full Venus Medtech company page
